David Allison

David Allison, Ph.D. joined 5 AM Ventures as a Principal in 2016 and was promoted to Partner in 2018. Previously, Dr. Allison was a Principal at Versant Ventures where he was involved in the firm’s investments in BlueRock Therapeutics, NeuWave (acquired by J&J), Crinetics (NASDAQ: CRNX), Aprea and BioTie (acquired by Acorda).

Prior to Versant, Dr. Allison worked with the healthcare team at Split Rock Partners and PTV Healthcare Capital. Before his venture career, he worked in the diagnostics and drug discovery business unit at SurModics and was a National Science Foundation Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory. At 5AM, Dr. Allison has been involved in the firms investments in Ceterix, CinCor Pharma, Crinetics (NASDAQ: CRNX), Impel Neuropharma, Magnetic Insight, Neurogastrx, Portal Instruments, and scPharmaceuticals (NASDAQ: SCPH). Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received a B.S.E in Biomedical Engineering from The University of Iowa. Dr. Allison is based in the San Francisco, CA office.